報價延遲最少15分鐘:2026/03/10 00:31 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
188.24 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
8.79/15.77
|
|
企業價值
33.71B
|
| 資產負債 |
|
每股賬面淨值
124.40
|
| 現金流量 |
|
現金流量率
0.08
|
| 損益表 |
|
收益
9.89B
|
|
每股收益
68.09
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis). |
